Asimilar Group Valuation

Is RSZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RSZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RSZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RSZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RSZ?

Key metric: As RSZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RSZ. This is calculated by dividing RSZ's market cap by their current revenue.
What is RSZ's PS Ratio?
PS Ratio	3.9x
Sales	UK£240.98k
Market Cap	UK£948.74k

RSZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.6x
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RSZ's PS Ratio compare to its peers?

The above table shows the PS ratio for RSZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2x
NAB Nabag	5.8x	n/a	€2.1m
ECS Eight Capital Partners	0.8x	n/a	€782.2k
LEH Lehner Investments	0.9x	n/a	€1.4m
VMR1 NSI Asset	0.4x	n/a	€3.0m
RSZ Asimilar Group	3.9x	n/a	€948.7k

Price-To-Sales vs Peers: RSZ is expensive based on its Price-To-Sales Ratio (3.9x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does RSZ's PS Ratio compare vs other companies in the DE Capital Markets Industry?

22 Companies	Price / Sales	Estimated Growth	Market Cap
MLP MLP	0.6x	2.3%	US$677.64m
MUX Mutares SE KGaA	0.1x	10.5%	US$554.91m
AR4 AURELIUS Equity Opportunities SE KGaA	0.2x	0.01%	US$500.05m
AR4 AURELIUS Equity Opportunities SE KGaA	0.02x	n/a	US$416.46m

22 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: RSZ is expensive based on its Price-To-Sales Ratio (3.9x) compared to the German Capital Markets industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is RSZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RSZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RSZ's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Yeahka

HK$4.3b

An investment holding company, provides payment and business services to merchants and consumers in the People’s Republic of China.

4YE

HK$1.18

-0.8%

-26.3%

Mutares SE KGaA

€503.9m

A private equity firm specializing in investments in secondary direct, special situations, bridge financing, recapitalization, distressed/vulture, management succession, reorganization, carve-outs, turnarounds, spin-offs and re-funding.

MUX

€22.40

-29.9%

Exor

€20.1b

Engages in the luxury goods, automotive, agricultural and construction equipment, commercial vehicles, and professional football businesses worldwide.

EYX

€93.50

-1.0%

4.6%